NEURORADIOLOGY / REVIEW PAPER
Medication-induced changes on magnetic resonance imaging of the brain
1
Department of Diagnostic Imaging, Institute of Mother and Child, Warsaw, Poland
2
Department of Radiology and Diagnostic Imaging, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland
Submission date: 2024-08-16
Acceptance date: 2024-08-19
Publication date: 2024-10-15
Corresponding author
Monika Bekiesinska-Figatowska
Department of Diagnostic Imaging, Institute of Mother and Child, Warsaw, Poland, e-mail: m.figatowska@mp.pl
Department of Diagnostic Imaging, Institute of Mother and Child, Warsaw, Poland, e-mail: m.figatowska@mp.pl
Pol J Radiol, 2024; 89: 488-501
KEYWORDS
TOPICS
ABSTRACT
In this review the authors focus on abnormal brain magnetic resonance imaging caused by drugs given to patients in any age group for any disease. The review includes viral infections with fever in children/infections in general, epilepsy, psychiatric diseases, multiple sclerosis, neoplasms, bone marrow/organ transplantations, total parenteral nutrition, vaccinations, oral contraceptives and other prothrombotic drugs, and gadolinium deposition. Knowledge of patients’ diseases and medications they receive is crucial to establish the correct diagnosis. The absence of these data in a referral for a brain MRI scan can result in completely wrong suspicions and unleash unnecessary, complicated, time-consuming and expensive diagnostics, causing additional stress in patients and their guardians.
REFERENCES (42)
1.
Lanska DJ. Drug-induced neurologic disorders. https://www.medlink.com/articl.... Updated 05.30.2023.
2.
Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc 2004; 1: 24-29.
4.
Singh P, Goraya JS, Gupta K, Saggar K, Ahluwalia A. Magnetic resonance imaging findings in Reye syndrome: case report and review of the literature. J Child Neurol 2011; 26: 1009-1014.
5.
Chapman J, Arnold JK. Reye syndrome. [Updated 2023 Jul 4]. In: StatPearls, Treasure Island (FL); 2024.
6.
Beutler AI. Aspirin use in children for fever or viral syndromes. Am Fam Physician 2009; 80: 1472-1474.
7.
Gordon N. Apparent cerebral atrophy in patients on treatment with steroids. Dev Med Child Neurol 1980; 22: 502-506.
8.
Biswas A, Krishnan P, Amirabadi A, Blaser S, Mercimek-Andrews S, Shroff M. Expanding the neuroimaging phenotype of neuronal ceroid lipofuscinoses. AJNR Am J Neuroradiol 2020; 41: 1930-1936.
9.
Ferner R, Day R, Bradberry SM. Phenytoin and damage to the cerebellum – a systematic review of published cases. Expert Opin Drug Saf 2022; 21: 957-977.
10.
Tamrazi B, Jeevak A. Your brain on drugs: imaging of drug-related changes in the central nervous system. Radiographics 2012; 32: 701-719.
11.
de Oliveira AM, Paulino MV, Vieira APF, McKinney AM, da Rocha AJ, Dos Santos GT, et al. Imaging patterns of toxic and metabolic brain disorders. Radiographics 2019; 39: 1672-1695.
12.
Na JH, Lee MJ, Lee CH, Lee YM. Association between epilepsy and Leigh syndrome with MT-ND3 mutation, particularly the m.10191T>C point mutation. Front Neurol 2021; 12: 752467. DOI: 10.3389/fneur.2021.752467.
13.
Sahu A, Sankhe S, Mittal K, Kamath N, Pg N, Sahu A. A pictorial review on reversible splenial lesions. Indian J Radiol Imaging 2021; 31: 3-9.
14.
Ryu HU, Chung JY, Shin BS, Kang HG. Lithium induced reversible splenial lesion in neuroleptic malignant syndrome like symptoms: two case reports. BMC Neurol 2020; 20: 164. DOI: 10.1186/s12883-020-01742-z.
16.
Narvid J, Rehani B, Talbott JF. Diagnostic performance of brain MRI in immune reconstitution inflammatory syndrome. J Neuroimaging 2016; 26: 303-308.
17.
Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y, et al. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry 2016; 87: 1138-1145.
18.
Rimkus CM, Schoeps VA, Boaventura M, Godoy LF, Apostolos-Pereira SL, Calich AL, et al. Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. Mult Scler Relat Disord 2021; 55: 103146. doi: 10.1016/j.msard.2021.103146.
19.
Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 949-959.
20.
Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 2007; 19: 108-114.
21.
Miyoshi T, Kondo T, Nishikori M, Kitawaki T, Kobayashi K, Fujimoto M, et al. Methotrexate-induced subacute myelopathy: a serious but treatable complication. J Clin Exp Hematop 2023; 63: 251-256.
22.
Isaac MFG, Alkhatib R, Ho CL. MRI characteristics of chemotherapy-related central neurotoxicity: a pictorial review. Insights Imaging 2024; 15: 12. DOI: 10.1186/s13244-023-01602-7.
23.
Singer S, Grommes C, Reiner AS, Rosenblum MK, DeAngelis LM. Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist 2015; 20: 806-811.
24.
de Havenon A, Joos Z, Longenecker L, Shah L, Ansari S, Digre K. Posterior reversible encephalopathy syndrome with spinal cord involvement. Neurology 2014; 83: 2002-6. doi: 10.1212/WNL.0000000000001026.
25.
Lapidus AH, Anderson MA, Harrison SJ, Dickinson M, Kalincik T, Lasocki A. Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. Leuk Lymphoma 2022; 63: 2364-2374.
26.
Smeralda CL, Gigli GL, Vogrig A, Marini A, Valente M. Tacrolimus-induced severe headache associated with diffuse leukoencephalopathy: Evidence for an immune-mediated pathogenesis. J Neuroimmunol 2019; 330: 55-58.
27.
Tan MG, Worley B, Kim WB, ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes. Am J Clin Dermatol 2020; 21: 163-172.
28.
Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 2013; 81: 1159-1165.
29.
Sharma AM, Birnhak A, Sanborn E, Bhana N, Kazmi K, Thon JM, et al. Neuroimaging mimics of anoxic brain injury: a review. J Neuroimaging 2023; 33: 467-476.
30.
Kumar G, Goyal MK. Lentiform fork sign: a unique MRI picture. Is metabolic acidosis responsible? Clin Neurol Neurosurg 2010; 112: 805-812.
31.
Zimny A, Zińska L, Bladowska J, Neska-Matuszewska M, Sąsiadek M. Intracranial lesions with high signal intensity on T1-weighted MR images – review of pathologies. Pol J Radiol 2013; 78: 36-46.
32.
Nagatomo S, Umehara F, Hanada K, Nobuhara Y, Takenaga S, Arimura K, et al. Manganese intoxication during total parenteral nutrition: report of two cases and review of the literature. J Neurol Sci 1999; 162: 102-105.
33.
Fitts W, Vogel AC, Mateen FJ. The changing face of osmotic demyelination syndrome: a retrospective, observational cohort study. Neurol Clin Pract 2021; 11: 304-310.
34.
Bekiesińska-Figatowska M, Bulski T, Rózyczka I, Furmanek M, Walecki J. MR imaging of seven presumed cases of central pontine and extrapontine myelinolysis. Acta Neurobiol Exp (Wars) 2001; 61: 141-144.
35.
Ferro JM, Bousser MG, Canhão P, Coutinho JM, Crassard I, Dentali F, et al.; European Stroke Organization. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology. Eur Stroke J 2017; 2: 195-221.
36.
Canedo-Antelo M, Baleato-González S, Mosqueira AJ, Casas-Martínez J, Oleaga L, Vilanova JC, et al. Radiologic clues to cerebral venous thrombosis. Radiographics 2019; 39: 1611-1628.
37.
Ramot Y, Nyska A, Spectre G. Drug-induced thrombosis: an update. Drug Saf 2013; 36: 585-603.
38.
Abdelhady M, Husain MA, Hawas Y, Elazb MA, Mansour LS, Mohamed M, et al. Encephalitis following COVID-19 vaccination: a systematic review. Vaccines (Basel) 2023; 11: 576. DOI: 10.3390/vaccines11030576.
39.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023; 22: 268-282.
40.
Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014; 270: 834-841.
41.
Starekova J, Pirasteh A, Reeder SB. Update on gadolinium based contrast agent safety, from the AJR special series on contrast media. AJR Am J Roentgenol 2024; 223: e2330036. DOI: 10.2214/AJR.23.30036.
42.
Rovira À, Wattjes MP. Gadolinium should always be used to assess disease activity in MS – No. Mult Scler 2020; 26: 767-769.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
